Piramal Pharma profit and loss

Latest FY26

Revenue: ₹8,869cr−3.1% on FY25
EBITDA: ₹922cr−36.2% on FY25
Net profit: −₹326cr₹91.1 cr in FY25
EPS: −₹2.46₹0.69 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	9,779	8,869	9,151	8,171	7,082	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	215	213	135	175	225
	9,993	9,082	9,286	8,347	7,307
	2,359	1,996	2,056	1,977	1,682
	1,468	1,431	1,417	1,176	952
	−227	−188	−241	−199	68.6
	2,576	2,416	2,307	2,030	1,896
	348	341	422	448	344
	888	831	816	741	677
	2,402	2,293	2,167	1,991	1,854
	9,814	9,120	8,944	8,164	7,474
	1,200	922	1,445	1,196	628
	312	90.4	628	456	−48.5
Profit
	179	−37.1	342	183	−168
	−217	−196	0.0	−62.8	−7.0
	−37.8	−233	342	120	−174
	210	162	310	185	110
	22.6	−12.2	13.4	−23.9	−44.1
	233	150	324	161	66.3
	61.1	57.2	72.9	59.5	54.3
	−209	−326	91.1	17.8	−186
	−271	−383	18.2	−41.7	−241
	237	338	79.8	56.7	176
	27.2	12.4	171	74.5	−10.7
	−209	−326	91.1	—	—
	−0.6	0.0	0.0	0.0	—
Per share
	−₹1.58	−₹2.46	₹0.69	₹0.14	−₹1.57
	−₹1.58	−₹2.46	₹0.68	₹0.14	−₹1.57
Other comprehensive income — detail
	237	338	79.8	—	—
	−21.9	−12.5	−8.2	−5.1	−3.4
	−5.5	−3.2	−2.1	—	—
	—	—	—	−1.3	−0.9
	280	391	89.9	62.3	189
	27.4	43.1	3.9	—	—
	—	—	—	1.8	11.0
	27.8	12.4	—	74.5	−10.7
	−0.6	0.0	—	0.0	0.0
Per share — as-filed variants
	−₹1.58	−₹2.46	₹0.69	₹0.14	−₹1.57
	−₹1.58	−₹2.46	₹0.68	₹0.14	−₹1.57
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	6,178	5,631	5,920	5,217	4,378
	63.2%	63.5%	64.7%	63.8%	61.8%
Adjusted (ex-exceptional items) — derived
	179	−37.1	342	183	−168
	−217	−196	0.0	−62.8	−7.0
	7.5	−130	91.1	42.9	−180
	₹0.06	−₹0.98	₹0.69	₹0.34	−₹1.51

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹30,628 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	7,081.6	8,171.2	9,151.2	8,869.1	9,778.6
Other Income	225.1	175.4	134.8	213.3	214.6
Total Income	7,306.7	8,346.6	9,286.0	9,082.4	9,993.3
Expenses
+ Cost of Materials Consumed	1,682.5	1,976.8	2,055.7	1,995.9	2,358.7
+ Purchases of Stock-in-Trade	952.2	1,175.8	1,417.3	1,430.5	1,468.5
+ Changes in Inventories	68.6	-198.6	-241.4	-187.8	-226.7
+ Employee Benefit Expense	1,896.4	2,029.5	2,307.5	2,415.9	2,575.8
+ Finance Costs	344.2	448.5	421.6	340.8	347.9
+ Depreciation & Amortisation	676.7	740.6	816.3	831.2	887.8
+ Other Expenses	1,853.7	1,991.4	2,167.2	2,293.0	2,402.2
Total Expenses	7,474.2	8,164.0	8,944.3	9,119.5	9,814.2
EBITDA	628.2	1,196.3	1,444.8	921.6	1,200.2
EBIT	-48.5	455.7	628.5	90.4	312.4
Profit
PBT before Exceptional Items	-167.5	182.6	341.7	-37.1	179.1
+ Exceptional Items	-7.0	-62.8	0.0	-196.1	-216.9
Pretax Income	-174.5	119.8	341.7	-233.3	-37.8
+ Current Tax	110.4	185.4	310.1	162.1	210.1
+ Deferred Tax	-44.1	-23.9	13.4	-12.2	22.6
Tax Expense	66.3	161.5	323.5	149.9	232.7
+ Share of Associates & JVs	54.3	59.5	72.9	57.2	61.1
Net Income	-186.5	17.8	91.1	-325.9	-209.4
+ Net Income — Continuing Ops	-240.8	-41.7	18.2	-383.1	-270.5
+ Other Comprehensive Income	175.8	56.7	79.8	338.4	236.6
Total Comprehensive Income	-10.7	74.5	171.0	12.4	27.2
Net Income to Common	—	—	91.1	-325.9	-208.8
Minority Interest	—	0.0	0.0	0.0	-0.6
Per Share
Basic EPS	-1.57	0.14	0.69	-2.46	-1.58
Diluted EPS	-1.57	0.14	0.68	-2.46	-1.58
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	79.8	338.4	236.6
+ Items NOT to be Reclassified to P&L	-3.4	-5.1	-8.2	-12.5	-21.9
+ Tax on Items NOT to be Reclassified	—	—	-2.1	-3.2	-5.5
+ Tax on Items NOT to be Reclassified — alt tag	-0.9	-1.3	—	—	—
+ Items to be Reclassified to P&L	189.4	62.3	89.9	390.8	280.4
+ Tax on Items to be Reclassified	—	—	3.9	43.1	27.4
+ Tax on Items to be Reclassified — alt tag	11.0	1.8	—	—	—
Comprehensive Income — Owners of Parent	-10.7	74.5	—	12.4	27.8
Comprehensive Income — Non-controlling Interests	0.0	0.0	—	0.0	-0.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	-1.57	0.14	0.69	-2.46	-1.58
Diluted EPS — Continuing Operations	-1.57	0.14	0.68	-2.46	-1.58
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	4,378.3	5,217.2	5,919.5	5,630.5	6,178.2
Gross Margin %	61.83	63.85	64.69	63.49	63.18
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-167.5	182.6	341.7	-37.1	179.1
− Exceptional Items (reconciliation)	-7.0	-62.8	0.0	-196.1	-216.9
Net Income Adj (tax-effected)	-179.5	42.9	91.1	-129.8	7.5
EPS Adj	-1.51	0.34	0.69	-0.98	0.06
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	1,193.3	1,323.0	1,324.4	1,327.2	1,328.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.